Sells handheld chemical-analysis devices that identify unknown materials for government agencies, public-safety users and life-sciences customers.
10-K for FY2025, filed Mar 9, 2026
Customers buy handheld devices and consumables, generally paying after shipment or delivery; support and warranty services are commonly paid in advance, at completion, or both.
10-K for FY2025, filed Mar 9, 2026
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗$56.2M
10-K for FY2025, filed Mar 9, 2026
$56.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Device sales revenue
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
65%
FY2022: 61%
|
Device sales revenue, FY2025
$36.7M Sources
|
Sold outright |
|
Recurring revenue
Mix
10-K for FY2025, filed Mar 9, 2026 |
35%
FY2022: 34%
|
Recurring revenue, FY2025
$19.4M Sources
|
Mix |
|
Contract revenue
|
0.2%
FY2022: 5.1%
|
Contract revenue, FY2025
$117K Sources
|
Government agencies and public-safety users are the main buyers, with life sciences customers also served. The company sells directly and through channel partners, including partners used when a U.S. government contract vehicle is required.
10-K for FY2025, filed Mar 9, 2026
Yes. It kept 35 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$24.6M.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$4.6MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
908 Devices updates its full year revenue guidance range to $68.5 million to $70.0 million (from $68.0 million to $70.0 million…View ↗
8-K, filed May 6, 2026
On May 4, 2026 (the “Closing Date”), 908 Devices Inc. (the “Company”) completed its acquisition of NIRLAB SA, a corporation organized under…View ↗
Growing. Revenue grew 33% in 4 years, from $42.2M in FY2021 to $56.2M in FY2025, about 7% a year.
Desktop portfolio sale
The older report described handheld and desktop Mass Spec devices for life-sciences and bioprocessing uses. The latest report centers on handheld devices; the company says it sold its Desktop Portfolio.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 9, 2026
Optical spectroscopy added
The older report presented Mass Spec as the company's analytical platform. The latest report adds optical spectroscopy, including technologies obtained with RedWave.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 9, 2026We have developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need.…View ↗
Competes with Agilent, Bruker, Danaher, Inficon, Teledyne, Rigaku, and Thermo Fisher Scientific
10-K for FY2025, filed Mar 9, 2026We have a range of competitors extending from small, privately held companies with single-point solutions to large, publicly-held…View ↗
Loading...